GLP-1 & Glucagon Dual Agonist | Weight Loss & Metabolic Research | For Research Use Only

Mazdutide (also known as IBI362) is a cutting-edge dual agonist targeting both GLP-1 (glucagon-like peptide-1) and glucagon receptors, developed for advanced research into obesity, type 2 diabetes, and metabolic syndrome. This dual mechanism mimics the natural balance of satiety and energy expenditure by combining appetite suppression (GLP-1 pathway) with enhanced thermogenesis and fat oxidation (glucagon pathway).

Mazdutide is part of the new generation of incretin-based compounds showing superior weight loss outcomes in clinical research compared to single agonists like Semaglutide or Tirzepatide.

🔍 Key Features

• Dual GLP-1/Glucagon Receptor Agonist – Enhanced metabolic activity

• Promotes Weight Loss by Reducing Appetite & Increasing Energy Use

• Improves Insulin Sensitivity & Glucose Control

• Supports Lipid Metabolism & Reduces Visceral Fat

• Potent Anti-Obesity Effects Under Investigation

⚙️ Compound Details

• Compound Name: Mazdutide (IBI362)

• CAS Number: 2748043-91-7

• Molecular Formula: Not publicly disclosed (complex peptide structure)

• Molecular Weight: High molecular weight peptide (proprietary data)

• Purity: ≥ 98% (HPLC Verified)

• Form: Lyophilised white/off-white powder

• Unit Size: 10mg per vial

🧊 Storage & Handling

• Storage (lyophilised): Store at –20°C, protected from light and moisture

• Reconstitution: Use bacteriostatic water or sterile saline

• Post-Reconstitution: Store at 2–8°C and use within 7–10 days

• Avoid: Exposure to heat, air, and multiple freeze-thaw cycles

⚠️ For Research Use Only

Mazdutide – 10mg is intended strictly for scientific and investigational research purposes only. It is not for human use or medical application. Handle with appropriate lab safety protocols.